

Neuroendokrine Tumoren:

Etablierung neuer Biomarker für Diagnostik und Therapie neuroendokriner Tumoren (S. 8–10)

Red.

1. Al-Toubah T et al. Sensitivity and Specificity of the NETest: A Validation Study. *Neuroendocrinol* 2020; 111: 580–85
2. Modlin IM et al. The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors. *Endocrinol Metab Clin N Am* 2018; 47: 485–504
3. Schueller F et al. The Role of miRNAs in the Pathophysiology of Liver Diseases and Toxicity. *Int J Mol Sci* 2018; 19: 261
4. Lu J et al. MicroRNA expression profiles classify human cancers. *Nature* 2005; 435: 834–38
5. Calin G et al. A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia. *N Engl J Med* 2005; 353: 1793–801
6. Rupaimoole R et al. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. *Nat Rev Drug Discov* 2017; 16: 203–22
7. Cavalcanti E et al. Altered miRNAs Expression Correlates With Gastroenteropancreatic Neuroendocrine Tumors Grades. *Front Oncol* 2020; 10: 1187
8. Mairinger F et al. Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: Results of a profiling study. *Mod Pathol* 2014; 27: 1632–40
9. Xiong Y et al. MicroRNA-29a Inhibits Growth, Migration and Invasion of Melanoma A375 Cells In Vitro by Directly Targeting BMI1. *Cell Physiol Biochem* 2018; 50: 385–97
10. Bondgaard A-LRØ et al. Different expression of EZH2, BMI1 and Ki67 in low and high grade neuroendocrine tumors of the lung. *Cancer Biomark* 2012; 11: 123–28
11. Ruebel K et al. MicroRNA expression in ileal carcinoid tumors: Downregulation of microRNA-133a with tumor progression. *Mod Pathol* 2010; 23: 367–75
12. Miller HC et al. MicroRNAs associated with small bowel neuroendocrine tumours and their metastases. *Endocr Relat Cancer* 2016; 23: 711–26
13. Mandal R et al. Analysis of miR-96 and miR-133a Expression in Gastrointestinal Neuroendocrine Neoplasms. *Endocr Pathol* 2017; 28: 345–50
14. Hellberg T et al. Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors. *PLoS ONE* 2020; 15: e0244504
15. Roldo C et al. MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors Are Associated with Distinctive Pathologic Features and Clinical Behavior. *J Clin Oncol* 2006; 24: 4677–84
16. Thorns C et al. Global microRNA profiling of pancreatic neuroendocrine neoplasias. *Anticancer Res* 2014; 34: 2249–54
17. Oberg K et al. Consensus on biomarkers for neuroendocrine tumour disease. *Lancet Oncol* 2015; 16: e435–e446
18. Yao JC et al. Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus. *J Clin Endocrinol Metab* 2011; 96: 3741–49
19. Kidd M et al. Chromogranin A: Any relevance in neuroendocrine tumors? *Curr. Opin. Endocrinol. Diabetes Obes* 2016; 23: 28–37

20. Lanford RE et al. Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection. *Science* 2010; 327: 198–201
 21. Janssen HLA et al. Treatment of HCV Infection by Targeting MicroRNA. *N Engl J Med* 2013; 368: 1685–94
 22. Geisler L et al. The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors. *Int J Mo Sci Review* 2021; 22: 8568
-

Supportivtherapie:

Uroonkologische Schmerztherapie (S. 24–25)

M. Beintker

1. Beintker M. *UroForum* 12/2019: 24–25
2. Beintker M, in Harzmann R: *Schmerztherapie und Palliativmedizin in der Urologie*. ecomed 2000: 64–69
3. Moormann O. Supportiv- und Schmerztherapie in Albers P, Hohenfellner M und Kuczyk M: 2. Urologie-Update-Seminar UROUPDATE 2009
4. Nauck F, Eulitz N. Tumorschmerztherapie. *Schmerz* 21; 2007: 359–72
5. Stiehl M. Der Tumorschmerzpatient in der Praxis. *ComMed Healthcare* 2002